Aquestive Therapeutics (AQST) Total Current Liabilities (2017 - 2026)

Aquestive Therapeutics' Total Current Liabilities history runs 10 years deep, the most recent figure standing at $31.8 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 73.53% year-over-year to $31.8 million; the TTM figure through Mar 2026 stood at $31.8 million (up 73.53% YoY), while the FY2025 annual figure was $47.6 million, up 152.36% from the prior year.
• Total Current Liabilities was $31.8 million for Q1 2026 at Aquestive Therapeutics, down from $47.6 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $47.6 million in Q4 2025 to a low of $13.9 million in Q2 2024.
• Historically, Total Current Liabilities has averaged $27.3 million across 5 years, with a median of $24.2 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Total Current Liabilities plunged 64.05% in 2024, then jumped 152.36% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $39.5 million in 2022, then slumped by 53.68% to $18.3 million in 2023, then increased by 3.04% to $18.9 million in 2024, then surged by 152.36% to $47.6 million in 2025, then plunged by 33.3% to $31.8 million in 2026.
• The last three Total Current Liabilities figures came in at $31.8 million (Q1 2026), $47.6 million (Q4 2025), and $25.6 million (Q3 2025), per Business Quant data.